Trials
1 active
1 in total
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “SYS6052 is a recombinant herpes zoster vaccine (CHO cell) developed by CSPC Megalith Biopharmaceutical Co., Ltd . Its active ingredient is the VZV glycoprotein E (gE) recombinantly expressed in CHO cells, and it is intended for clinical use in the prevention of herpes zoster.”In the company’s words, NCT07892989 on ClinicalTrials.gov
- Tested for
- Herpes Zoster
- Main trialPhase 1/2
- “Herpes zoster is caused by the reactivation of latent varicella-zoster virus (VZV) which stays in latency after its primary infection. Immunosenescence contributes significantly to elevating morbidity associated with aging. Vaccination plays a key role in reducing the disease burden of zoster and the associated complications. We are conducting a study entitled "A Randomized, Blinded, Controlled, Phase I/II Clinical Trial to Evaluate the Safety and Immunogenicity of SYS6052 (Recombinant Herpes Zoster Vaccine (CHO Cell)) Administered to Participants Aged 40 Years and Above".”In the company’s words, NCT07892989 on ClinicalTrials.gov
Other drugs for Herpes Zoster
- HZ/su vaccineGSK · Phase 3
- Recombinant Zoster VaccineMAXVAX Biotechnology Limited Liability Company · Phase 3
- CVI-VZV-001Aribio Lab Co., Ltd. · Phase 2
- SYS6017CSPC · Phase 2
- Z-1018Dynavax Technologies Corporation · Phase 1/2
- HZ VaccineShenzhen Shenxin Biotechnology Co., Ltd · Phase 2
Coming up1
- 31 Jul 2027Phase 1/2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1/2Not yet recruiting | 31 Jul 2027 | Immunogenicity and Safety of SYS6052 in the Participants Aged 40 Years and Above |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026